Swedish Orphan Biovitrum (SOBIS) Stock Overview
A biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SOBIS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Swedish Orphan Biovitrum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 284.00 |
| 52 Week High | SEK 344.80 |
| 52 Week Low | SEK 260.00 |
| Beta | 0.29 |
| 1 Month Change | 1.79% |
| 3 Month Change | -1.01% |
| 1 Year Change | -7.37% |
| 3 Year Change | 29.62% |
| 5 Year Change | 58.13% |
| Change since IPO | 730.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| SOBIS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 3.2% | 9.0% | 2.2% |
| 1Y | -7.4% | 9.8% | 13.4% |
Return vs Industry: SOBIS underperformed the UK Biotechs industry which returned 9.8% over the past year.
Return vs Market: SOBIS underperformed the UK Market which returned 13.4% over the past year.
Price Volatility
| SOBIS volatility | |
|---|---|
| SOBIS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.4% |
Stable Share Price: SOBIS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine SOBIS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1939 | 1,937 | Guido Oelkers | www.sobi.com |
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma.
Swedish Orphan Biovitrum AB (publ) Fundamentals Summary
| SOBIS fundamental statistics | |
|---|---|
| Market cap | SEK 109.04b |
| Earnings (TTM) | SEK 4.37b |
| Revenue (TTM) | SEK 26.97b |
Is SOBIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOBIS income statement (TTM) | |
|---|---|
| Revenue | SEK 26.97b |
| Cost of Revenue | SEK 5.81b |
| Gross Profit | SEK 21.16b |
| Other Expenses | SEK 16.79b |
| Earnings | SEK 4.37b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 23, 2025
| Earnings per share (EPS) | 12.58 |
| Gross Margin | 78.45% |
| Net Profit Margin | 16.21% |
| Debt/Equity Ratio | 31.9% |
How did SOBIS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 16:25 |
| End of Day Share Price | 2025/09/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Swedish Orphan Biovitrum AB (publ) is covered by 32 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Rosie Turner | Barclays |
| Brian Balchin | Barclays |